Spero Therapeutics (NASDAQ:SPRO) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a buy rating to a hold rating in a research report report published on Saturday morning.

Several other research firms have also commented on SPRO. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. Zacks Research downgraded shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 13th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $5.00.

Spero Therapeutics Trading Up 2.2%

Shares of SPRO stock opened at $2.31 on Friday. Spero Therapeutics has a twelve month low of $0.51 and a twelve month high of $3.22. The stock has a market cap of $130.15 million, a P/E ratio of -2.92 and a beta of 1.48. The stock has a 50 day moving average of $2.31 and a 200 day moving average of $2.31.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.12. The business had revenue of $5.44 million for the quarter, compared to analysts’ expectations of $12.00 million. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. On average, research analysts predict that Spero Therapeutics will post -1.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Spero Therapeutics news, insider Esther Rajavelu sold 40,270 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $2.37, for a total transaction of $95,439.90. Following the completion of the sale, the insider directly owned 869,450 shares in the company, valued at approximately $2,060,596.50. The trade was a 4.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Spero Therapeutics

A number of institutional investors have recently made changes to their positions in SPRO. Invesco Ltd. acquired a new position in Spero Therapeutics in the 2nd quarter valued at $43,000. Dimensional Fund Advisors LP purchased a new stake in shares of Spero Therapeutics during the third quarter worth $55,000. Quadrature Capital Ltd purchased a new stake in shares of Spero Therapeutics during the second quarter worth $90,000. Axxcess Wealth Management LLC acquired a new stake in shares of Spero Therapeutics in the second quarter valued at about $94,000. Finally, Capital Asset Advisory Services LLC acquired a new stake in shares of Spero Therapeutics in the second quarter valued at about $94,000. 25.60% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.